CTIS2023-508841-42-00进行中（未招募）1 期
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments - CPDR001X2X01B
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 119
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Signed informed consent must be obtained prior to participation in the study., Subject is currently enrolled in a pre-defined Novartis-sponsored study and is receiving spartalizumab as single agent or in combination with other study treatment., Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator., Subject has demonstrated compliance, as assessed by the investigator, with the parent protocol requirements., Subject is willing and able to comply with the scheduled visits and treatment plans.
排除标准
- •Subject has been permanently discontinued from spartalizumab in the parent protocol for any reason other than enrollment in the CPDR001X2X01B study., Subject does not meet the criteria specified in the parent protocol criteria for continued study treatment.
研究者
相似试验
进行中（未招募）
1 期
A rollover study for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib alone or in combination with other agentsEUCTR2016-000293-37-FRovartis Pharma Services AG40
招募中
2 期
An open-label, multi-center rollover protocol for patients
who have participated in a Novartis-sponsored ribociclib
(LEE011) study and are continuing to benefit from
ribociclib as single agent or in combination with other
investigational treatments2024-511125-61-00Novartis Pharma AG1
招募中
1 期
An open-label, multi-center rollover protocol for patientswho have participated in a Novartis-sponsored ribociclib(LEE011) study and are continuing to benefit fromribociclib as single agent or in combination with otherinvestigational treatmentsCTIS2024-511125-61-00ovartis Pharma AG4
招募中
不适用
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatmentssolid cancer(s)malignancy10027655NL-OMON51829ovartis1
进行中（未招募）
1 期
A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.Biliary atresiaMedDRA version: 20.0Level: LLTClassification code 10004653Term: Biliary atresiaSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10004654Term: Biliary atresia, congenitalSystem Organ Class: 100000004850EUCTR2014-004693-42-FIIntercept Pharmaceuticals, Inc.72